GSPOA World Health Summit Workshop, Usman
Download as PPT, PDF•0 likes•313 views
This document summarizes a presentation given by Usman A. Mushtaq on global strategies for public health innovation and intellectual property. The presentation argues that current IP rights do not do enough to empower low and middle income countries to address their disease burdens and health inequities. It provides the rationale that restricted sharing of biotechnology and IP in LMICs violates human rights and ethics. The strategy proposes over 100 action points led by WHO to build LMIC capacity, utilize flexibilities in IP laws, and promote needs-based innovation. However, challenges remain in implementation across governing bodies and reconciling trade and health interests. Student advocacy groups are working to address these issues and promote curriculum on global health needs.
GSPOA World Health Summit Workshop, Usman
- 1. Global Strategy and Plan of Action for Public Health, Innovation and Intellectual Property A Student’s Perspective Usman A. Mushtaq Vice president of External Affairs, International Federation of Medical Students Association Youth commissioner, The Lancet-University of Oslo and Harvard Public Health School Commission on Global Governance for Health World Health Summit 2012, Berlin
- 2. Are our innovation & intellectual property rights doing enough to empower LMICs to fight such a disease burden, or more importantly, to merge the growing gap in stark health inequities?
- 3. BUT Rationale for the strategy • Health inequity: Restricted sharing of biotechnical and intellectual advancement in LMICs--> bifurcates into richer countries with easier access vs. poorer with limited access. • Chronic+infectious disease double- burden: Defeats the inherent purpose of innovation--> to ameliorate disease burden and improve health care accessibility and technical prowess in LMICs
- 4. BUT Rationale for the strategy • Ethical & Human Rights Considerations: • The Universal Declaration of Human Rights:“Right to share in scientific advancement and its benefits..".Denying access to advanced health care and resources is an ethical violation. • Promote innovation in research and development paradigms unique to LMICs: Which will help in focused needs-based development and accessible medicines.
- 5. Implementation • Over 100 action points over a broad area involving numerous governing bodies. • WHO passionately leading the work with progress of implementation. • Many initiatives proposed, • capacity building LMIC on utilizing the TRIPS flexibilities • Open source licensing, patent pool, prizes • Was a step to the Consultative Expert Working Group on Research and Development
- 6. Some Challenges • The strategy so broad that it makes it vague? • Despite the increased focus on the issue of access and innovation, progress still remains slow. • Many of the solutions lays outside the working area of WHO and falls under other global governing bodies
- 7. Paradoxes of Health and Trade k on reconcile divergent interests? • How do member states work on reconcile divergent interests? • Do member states prioritize health over trade? • How can interests around protection of knowledge for the sake of trade and investment be reconciled with efforts to produce global public goods?
- 8. Student-led advoacy Iconic development International Federation of Medical Students’ Associations
- 9. Student-led advoacy Iconic development Universities Allied for Essential Medicines •UAEM Global Health Impact Report Card: Measures licensure and IP restrictions pertinent to Universities medical innovations. •Evaluates on three parameters: • 1. Access: Are licensed/IP rights protected biomedical technologies developed by Universities accessible and affordable to LMICs?
- 10. Student-led advoacy Iconic development • 2. Innovation: How pertinent is the development to needs of LMICs double disease-burden or poverty afflictions? • 3. Curriculum: Does the development do justice to academia's calling to promote global health education?
- 11. Student-led advoacy Iconic development Students from McMaster University
- 12. Looking ahead
- 13. Recommendations from the CEWG on R&D John-Arne Røttingen, CEWG chair: “If the price of health products continues to reflect the full cost of R&D products, these products will never be affordable for those that need them most. We therefore need to do two things: to delink the cost of research from the price of the product, and to develop mechanisms in addition to intellectual property rights to incentivize research investment in these diseases.”
- 14. Post 2015 development agenda Where does the issue of access fit in?
- 16. Thank you for listening!